scholarly journals Non-invasive Prenatal Testing for Hemoglobin Bart’s Hydrops Fetalis Syndrome (SEA Deletion) Using Cell-Free Fetal DNA in Maternal Plasma: Systematic Review and Meta-analysis

2018 ◽  
Vol 18 (04) ◽  
Author(s):  
Wittaya Jomoui
2016 ◽  
Vol 95 (8) ◽  
pp. 1341-1350 ◽  
Author(s):  
Mandana Zafari ◽  
Mehrnoush Kosaryan ◽  
Pooria Gill ◽  
Abbass Alipour ◽  
Mohammadreza Shiran ◽  
...  

2015 ◽  
Vol 35 (5) ◽  
pp. 471-476 ◽  
Author(s):  
A. Alberti ◽  
L. J. Salomon ◽  
M. Le Lorc'h ◽  
A. Couloux ◽  
L. Bussières ◽  
...  

Genes ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 15
Author(s):  
Luigi Carbone ◽  
Federica Cariati ◽  
Laura Sarno ◽  
Alessandro Conforti ◽  
Francesca Bagnulo ◽  
...  

Fetal aneuploidies are among the most common causes of miscarriages, perinatal mortality and neurodevelopmental impairment. During the last 70 years, many efforts have been made in order to improve prenatal diagnosis and prenatal screening of these conditions. Recently, the use of cell-free fetal DNA (cff-DNA) testing has been increasingly used in different countries, representing an opportunity for non-invasive prenatal screening of pregnant women. The aim of this narrative review is to describe the state of the art and the main strengths and limitations of this test for prenatal screening of fetal aneuploidies.


2015 ◽  
Vol 43 (2) ◽  
pp. 228-240 ◽  
Author(s):  
Rachel Rebouché

A regulatory moment for prenatal health care is here. An increasing amount of legislative attention has concentrated on the decisions pregnant women make after prenatal testing. The impetus for this legislation is a new non-invasive prenatal genetic test (NIPT). From the beginning of pregnancy, cell-free fetal DNA travels across the placental lining into the mother’s bloodstream, increasing in quantity as the pregnancy progresses. Laboratories can now analyze that DNA for chromosomal abnormalities and for fetal sex at 10 weeks of gestation. NIPT, which relies on a sample of the pregnant woman’s blood, is painless, occurs early in pregnancy, and is available for clinical and commercial use. In 2013, major health insurance plans began to cover NIPT for certain populations of women, such as women over 35 years old. And private companies have started marketing prenatal testing kits directly to consumers, who return a blood sample from the prospective mother to a company laboratory.


2021 ◽  
Vol 7_2021 ◽  
pp. 10-18
Author(s):  
Bespalova O.N. Bespalova ◽  
Butenko M.G. Butenko ◽  
Pachulia O.V. Pachulia ◽  
Glotov A.S. Glotov ◽  
Kogan I.Yu. Kogan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document